Clinical Research Directory
Browse clinical research sites, groups, and studies.
BRIGHT-Child TB: Short-Course Treatment for Non-Severe Pulmonary Tuberculosis in Children
Sponsor: Huashan Hospital
Summary
The goal of this Phase II, multicenter, open-label, randomized controlled trial is to evaluate the efficacy and safety of short-course treatment regimens for children with non-severe, drug-susceptible pulmonary tuberculosis. The main questions it aims to answer are: * Do the 3-month bedaquiline, delamanid, contezolid, and pyrazinamide regimen (BDCZ) and the 4-month fixed-dose combination (FDC) regimen provide effective treatment, as measured by tuberculosis-free survival at 12 months after treatment initiation? * What are the safety profiles of the two short-course regimens, as measured by the incidence of grade 3 or higher adverse events? * How do the short-course regimens compare with the standard 6-month treatment regimen in terms of treatment success, treatment failure, recurrence, and tuberculosis-free survival during follow-up? Researchers will compare the 3-month BDCZ regimen and the 4-month FDC regimen with the standard 6-month treatment regimen to evaluate their efficacy and safety in children with non-severe, drug-susceptible pulmonary tuberculosis. Participants will be randomly assigned to one of three treatment groups and will receive the allocated regimen. They will undergo clinical assessments and safety monitoring during treatment, with follow-up to assess treatment outcomes, tuberculosis recurrence, and tuberculosis-free survival at 12, 18, and 24 months after treatment initiation.
Official title: A Multicenter, Randomized, Controlled Trial to Evaluate the Efficacy and Safety of a Short-Course Treatment Regimen for Non-Severe Pulmonary Tuberculosis in Children (BRIGHT-Child TB)
Key Details
Gender
All
Age Range
3 Months - 18 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2026-07-08
Completion Date
2028-11-30
Last Updated
2026-10-26
Healthy Volunteers
No
Conditions
Interventions
4-month FDC-based regimen
4-month fixed-dose combination (FDC) regimen
3-month BDCZ regimen
3-month bedaquiline, delamanid, contezolid, and pyrazinamide (BDCZ) regimen
Standard 6-month treatment regimen
Standard 6-month treatment regimen, namely 2HRZ(E)/HR.
Locations (13)
Fuzhou Tuberculosis Prevention and Control Hospital of Fujian Province
Fuzhou, Fujian, China
Guangzhou Chest Hospital
Guangzhou, Guangdong, China
Guiyang Public Health Clinical Center
Guiyang, Guizhou, China
Third People's Hospital of Liupanshui
Liupanshui, Guizhou, China
Zunyi Infectious Diseases Hospital
Zunyi, Guizhou, China
The Fifth People's Hospital of Suzhou
Suzhou, Jiangsu, China
Ganzhou Fifth People's Hospital
Ganzhou, Jiangxi, China
The Fourth People's Hospital of Qinghai Province
Xining, Qinghai, China
Shandong Public Health Clinical Center
Jinan, Shandong, China
Huashan Hospital
Shanghai, Shanghai Municipality, China
The First Affiliated Hospital of Shihezi University
Shihezi, Xinjiang Uygur Autonomous Region, China
Hangzhou Red Cross Hospital
Hangzhou, Zhejiang, China
The Children's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China